Aspirin-associated iron loss as an anticancer mechanism

Medical Hypotheses

Volumn 74, Issue 1, 2010, Pages 78-80

  Mascitelli, Luca ^a   Pezzetta, Francesca ^b   Sullivan, Jerome L ^c  

^a Medical Service   (Italy)

^b Ospedale Civile di Tolmezzo   (Italy)

^c UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FERRITIN; IRON;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; HUMAN; IRON DEPLETION; IRON STORAGE; LOW DRUG DOSE; NEOPLASM; PRIORITY JOURNAL; REPEATED DRUG DOSE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ASPIRIN; CLINICAL TRIALS AS TOPIC; FERRITINS; FREE RADICALS; HUMANS; INCIDENCE; IRON; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MODELS, THEORETICAL; NEOPLASMS;

EID: 70549102374     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.07.047     Document Type: Article

References (16)

1. Cuzick J., Otto F., Baron J.A., Brown P.H., Burn J., Greenwald P., et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10 5 (2009) 501-507
2. Elwood P.C., Gallagher A.M., Duthie G.G., Mur L.A., and Morgan G. Aspirin, salicylates, and cancer. Lancet 373 9671 (2009) 1301-1309
3. Sullivan J.L. Iron, aspirin, and heart disease risk [letter]. JAMA 247 6 (1982) 751
4. Sullivan J.L. The coxib crisis. Iron, aspirin and heart disease risk revisited. J R Soc Med 100 7 (2007) 346-349
5. Moore R.A., Derry S., and McQuay H.J. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther 10 1 (2008) R7
6. Fleming D.J., Jacques P.F., Massaro J.M., D'Agostino Sr. R.B., Wilson P.W., and Wood R.J. Aspirin intake and the use of serum ferritin as a measure of iron status. Am J Clin Nutr 74 2 (2001) 219-226
7. Milman N., Ovesen L., Byg K., and Graudal N. Iron status in Danes updated 1994. I: prevalence of iron deficiency and iron overload in 1332 men aged 40-70 years. Influence of blood donation, alcohol intake, and iron supplementation. Ann Hematol 78 9 (1999) 393-400
8. Liu J.M., Hankinson S.E., Stampfer M.J., Rifai N., Willett W.C., and Ma J. Body iron stores and their determinants in healthy postmenopausal US women. Am J Clin Nutr 78 6 (2003) 1160-1167
9. Zacharski L.R., Chow B.K., Howes P.S., Shamayeva G., Baron J.A., Dalman R.L., et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 100 14 (2008) 996-1002
10. Stevens R.G., Graubard B.I., Micozzi M.S., Neriishi K., and Blumberg B.S. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 56 3 (1994) 364-369
11. Coffman L.G., Parsonage D., D'Agostino R., Torti F.M., and Torti S.V. Regulatory effects of ferritin on angiogenesis. PNAS 106 2 (2009) 570-575
12. Hann H.W., Stahlhut M.W., and Blumberg B.S. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res 48 15 (1988) 4168-4170
13. Toyokuni S. Iron and carcinogenesis: from Fenton reaction to target genes. Redox Rep 7 4 (2002) 189-197
14. Yu Y., Kovacevic Z., and Richardson D.R. Tuning cell cycle regulation with an iron key. Cell cycle 6 16 (2007) 1982-1994
15. Yoshiji H., Nakae D., Mizumoto Y., Horiguchi K., Tamura K., Denda A., et al. Inhibitory effect of dietary iron deficiency on inductions of putative preneoplastic lesions as well as 8-hydroxydeoxyguanosine in DNA and lipid peroxidation in the livers of rats caused by exposure to a choline-deficient l-amino acid defined diet. Carcinogenesis 13 7 (1992) 1227-1233
16. Sullivan J. Is stored iron safe?. J Lab Clin Med 144 6 (2004) 280-284